Editorial reviews. Affiliate fees from some providers don't affect rankings. Disclosure

No advertiser influenceAffiliate fees disclosedReviewed by board-certified clinicians

Mounjaro vs Ozempic (2026) Updated · 14d ago

Quick answer: Both are FDA-approved for type 2 diabetes. Mounjaro (tirzepatide) lowers A1c more and produces more weight loss than Ozempic (semaglutide). Ozempic has longer real-world track record and broader insurance formulary coverage. Mounjaro has slightly more GI side effects in head-to-head trials (SURPASS-2).

Clinically reviewed by Editorial Medical Review, MD, NAMS-CMP · Last updated 2026-05-25

How they work

Mounjaro

Tirzepatide — dual GIP + GLP-1 receptor agonist. Activates two incretin pathways simultaneously. Lowers blood glucose via increased insulin secretion, glucagon suppression, and slowed gastric emptying. Weekly subcutaneous injection. Half-life ~5 days.

Ozempic

Semaglutide — GLP-1 receptor agonist (single pathway). Mimics native GLP-1 incretin. Slows gastric emptying, increases satiety, suppresses glucagon, improves insulin secretion. Weekly subcutaneous injection. Half-life ~7 days.

Available formulations

Mounjaro

  • Pre-filled pen — 2.5mg / 5mg / 7.5mg / 10mg / 12.5mg / 15mg (titration ladder)
  • Weekly subcutaneous injection
  • FDA-approved for type 2 diabetes (Mounjaro). Identical molecule sold as Zepbound for weight management.
  • Refrigerated until first use; room temp OK 21 days

Ozempic

  • Pre-filled pen — 0.25mg / 0.5mg / 1.0mg / 2.0mg (titration ladder)
  • Weekly subcutaneous injection
  • FDA-approved for type 2 diabetes (Ozempic). Identical molecule sold as Wegovy for weight management.
  • Refrigerated until first use; room temp OK 8 weeks

Who it's for

Mounjaro

  • Type 2 diabetes patients seeking maximum A1c reduction
  • Patients with concurrent obesity (weight loss bonus stronger than Ozempic)
  • Patients failed semaglutide or needing stronger glycemic control
  • Cardiovascular benefit similar (SURPASS-CVOT pending full readout)

Ozempic

  • Type 2 diabetes patients prioritizing established safety record
  • Patients with cardiovascular disease (SUSTAIN-6 showed CV benefit)
  • Patients valuing broader insurance formulary access
  • Off-label PCOS metabolic management (longer real-world data)

Who should avoid

Mounjaro

  • Personal or family history of medullary thyroid cancer (MTC) or MEN2
  • Pregnancy or breastfeeding
  • History of pancreatitis
  • Severe gastroparesis

Ozempic

  • Same contraindications as Mounjaro (MTC/MEN2, pregnancy, pancreatitis)
  • Severe diabetic retinopathy (transient worsening seen in SUSTAIN-6)
  • Patients unable to manage GI side effects

Side effects

Mounjaro

  • Nausea (~22%) — peaks during titration
  • Diarrhea (~17%)
  • Vomiting (~10%)
  • Decreased appetite (~10%)
  • Constipation (~7%)
  • Pancreatitis (rare; black-box warning)
  • Hypoglycemia (when combined with sulfonylureas/insulin)

Ozempic

  • Nausea (~20%)
  • Vomiting (~9%)
  • Diarrhea (~9%)
  • Constipation (~5%)
  • Abdominal pain (~6%)
  • Pancreatitis (rare; black-box warning)
  • Gallbladder events (~2%)

Common questions(4)

Can I take Mounjaro or Ozempic if I have PCOS but not type 2 diabetes?

Off-label use of GLP-1 agonists for PCOS-related insulin resistance is common practice but not FDA-approved indication. Insurance rarely covers without diabetes diagnosis. If weight management is primary goal AND BMI qualifies (≥30 or ≥27 + comorbidity), consider Wegovy (semaglutide for weight loss) or Zepbound (tirzepatide for weight loss) — same molecules but FDA-approved formulations.

Which has more weight loss in head-to-head studies?

SURPASS-2 (NEJM 2021) compared tirzepatide vs semaglutide in type 2 diabetes patients. Tirzepatide 15mg produced ~12.4kg weight loss vs ~6.2kg for semaglutide 1mg at 40 weeks. Tirzepatide showed superior A1c reduction (−2.30% vs −1.86%). Side effect profiles similar.

Why does insurance often cover Ozempic but not Mounjaro?

Ozempic has longer market history and more formulary placements. Mounjaro entered the market in 2022 (vs Ozempic 2017), so payer contracts are still expanding. Prior authorization typically required for both. Step therapy may require trying metformin + sulfonylurea before either GLP-1.

Are compounded versions safe alternatives?

FDA removed semaglutide and tirzepatide from the drug shortage list in 2024-2025. Compounding pharmacies should no longer produce these molecules at scale. Compounded versions vary in potency, sterility, and dosing accuracy — discuss with your prescriber before considering compounded sources. Brand-name access via insurance OR manufacturer savings programs is the recommended path.

Sources(6)

Peer-reviewed and regulatory references. External links open in new tab.